In 2022, we conducted an online survey of people with migraine in Aotearoa New Zealand
We received 579 responses. Following removal of incomplete responses and those unlikely to have migraine, we had 530 responses for analysis.
Aim of the survey
The aim of the survey was to collect data on:
types of acute and preventive medications used
non-medication acute and preventive treatments used
disability from migraine
impact of migraine on work
use of, access to and experience of health services
experiences of stigma
what could be improved for people with migraine.
Survey development and data collection
The survey was developed using existing questions, specifically the Migraine Identification test (ID-Migraine testTM), the Migraine Disability Assessment Scale (MIDAS), demographic questions used by Stats NZ and the Ministry of Health and qualitative (open-ended) questions. The survey questionnaire is available below.
The survey was available online from 22 August 2022 to 7 Oct 2022 via a link on the MFANZ website landing page. It was promoted through our social media channels and networks, including Health Navigator, Neurological Foundation, New Zealand Pain Society, and a large engineering firm through a staff newsletter.
Media articles linking to the survey webpage included a primary care electronic newsletter, an article by an AUT journalist and a press release on Scoop. For more information about the survey, see our methodology report.
We have published 23 key insight reports from the survey. To date, we’ve used the survey results as a New Zealand evidence-base in our Emgality application to Pharmac, had a 4th year medical student analysing the data for publication, and have submitted a research paper.